The OHSU Knight Cancer Institute has expanded its cancer research and care facilities to include a unit dedicated to serving patients participating in early-phase clinical trials. Harnessing the predictive power of preclinical models for oncology drug Shivaani Kummar's research works | Institute of Cancer Research, London Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. OHSU is an equal opportunity affirmative action institution. Our ability to move these projects forward and to take on new projects is limited by the available resources. Over the past six months, a multidisciplinary team has been coordinating patient experience, drug delivery, staffing schedules and equipment needed to support the range of clinical trials offered in the unit that span 14 different cancer disease groups. Expanding access to experimental cancer - Cancer Translated Caring for them drives me to work harder to develop more effective treatments that are better tolerated. OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . Dr. February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC Accepting new patients OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Having someone who understands the challenges is helpful.. Her research interests focus on developing novel therapies for cancer. Philanthropy will allow us to expand the number of ongoing projects, including those focusing on rare tumors, as well as take on more pre- and post-doctoral students to train the next generation of cancer researchers. We also share information about your use of our site with our trusted social media, advertising and analytics partners. They have a high school-aged daughter and middle school-aged son. Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid , 1 Web Browser Accessibility, An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer. The OHSU Knight Cancer Institute is part of regional, national and international research partnerships, offering patients local access to the latest advances and clinical trials. (h.c.), Ph.D., FAACR. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. Shivaani Kummar: STUDY00021766: . Notice of Privacy Practices edu h-index 8546 Citations 49 h-index 1996 2023 Research activity per year Overview Fingerprint Network Grants (5) Publications (174) Similar Profiles (1) If you made any changes in Pure these will be visible here soon. We are delighted she has chosen to join us, said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. lions led by donkeys for and against. She received her medical degree from Lady Hardinge Medical College and has been in practice for . 2001-2023 OHSU. billing andinsurancesection of our site, Medical Oncology and Hematology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, American Board of Internal Medicine Board Certified in Internal Medicine, 1995-2005, Board Recertified in Internal Medicine, 2005-2015, Board Certified in Medical Oncology, 1998-2008, Board Recertified in Medical Oncology, 2008-2018; 2018-2028 Board Certified in Hematology, 2002-2012, Member, American Society of Clinical Oncology, Member, American Association for Cancer Research. Shivaani Kummar. 12 Reviews). The Division of Hematology and Medical Oncology is headed byShivaani Kummar, M.D., FACPand composed of many sections: Kathleen Beebe Dr. Shivaani Kummar, MD | Palo Alto, CA | Oncologist | US News Doctors We have a billion reasons why you should join us. OHSU Foundation P.O. This center will be for the community, and we hope people will reach out to be a part of it. DR. SHIVAANI KUMMAR NPI 1053612341 - NPI Profile boundtree continuing education; can you be charged under ucmj after discharge Increasing (gender) diversity on a journal: a case study - Elsevier Connect Support the Abortion Care and Training Fund. Administrative Coordinator, Margaret Rogers The new early-phase research unit completes this expansion in the building. Each faculty member comes with a unique background, which often propels him or her into medicine and a particular . shivaani kummar ohsu email - sosfoams.com Husband-wife team from Stanford University tapped to lead - OHSU News (OHSU/Kristyna Wentz-Graff). Uncategorized . S Kummar, R Kinders, L Rubinstein, RE Parchment, AJ Murgo, J Collins, Journal of Soil and Water Conservation 53 (3), 230-240. Only fill in if you are not human. Kummars remarkable accomplishments, combined with her ability to connect with people and her clear vision for how to grow the hematology-oncology division, made her our top candidate. . . shivaani kummar ohsu email - eachoneteachoneffi.com Together they have built a strong record of discovery, innovation and care. . Shivaani Kummar - PMWC Precision Medicine World Conference Developing new treatments for cancer is a complex, multidisciplinary process that truly takes a village. What are the latest results? Dr. Shivaani Kummar - Medical Oncology, Portland OR She shares our urgency to better understand how research and drug development can help the patients who desperately need better treatments, today.. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Increasing patient participation in oncology clinical trials, A Novel Artificial IntelligencePowered Method for Prediction of Early Recurrence of Prostate Cancer after Prostatectomy and Cancer Drivers, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas, Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer. Shivaani Kummar Aim: Timely recruitment of eligible participants is essential for the success of clinical trials, with insufficient accrual being the leading cause for premature termination of. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. 2001-2023 OHSU. As an oncologist, Dr. Kummar manages and oversees the treatment of a cancer patient after he or she has been diagnosed with the disease. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Across OHSU, doctors and researchers are reimagining early disease detection. OHSU is an equal opportunity affirmative action institution. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. This new unit allows us to centralize everything in a setting designed for a patients convenience and comfort, said Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute. Shivaani Kummar - .. - Oregon Health & Science University - ZoomInfo Stat4Onc Annual Symposium (2022) - University Of Connecticut Equipment. Notice of Privacy Practices OHSU is an equal opportunity affirmative action institution. Education & Training Oregon Health & Science University Fellowship, Hematology and Medical Oncology, 1995 - 1997 New York Presbyterian Hospital (Columbia Campus) Residency, Internal Medicine, 1990 - 1993 Harvard Medical School Class of 1989 Shivaani Kummar Oregon Health & Science University SHIVAANI KUMMAR, 207RX0202X - Medical Oncology Doctors & Physicians in PORTLAND, OR. Accueil; Solution; Tarif; PRO; Mon compte; France; Accueil; Solution OHSU is an equal opportunity affirmative action institution. What excites you about coming to work in the morning? Nature reviews Drug discovery 9 (11), 843-856. Faculty Spotlight - Shivaani Kummar, MD, FACP | Department of Medicine Sort. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Password. Shivaani Kummar Professor Professor, Knight Cancer Institute Knight Cancer Translational Oncology Program Email kummar @ ohsu. Shivaani Kummar M.D., FACP | Health care provider | OHSU OHSU Knight Cancer Institute Archives - The Cancer Letter Where is Dr. Shivaani Kummar located? Together they form a unique fingerprint. The institute is involved with more than 400 clinical trials, including 113 early-phase trials. Bergan, R., Coussens, L., McWeeney, S., Spellman, P., Streeter, P., Winters-Stone, K., Bagby, G., Mori, M., Corless, C., Harrington, C., Hoatlin, M., Koop, D., Magun, B., Druker, B., Shannon, J. Ashok Muralidaran, M.D., discusses how his passions inspire his work as a pediatric cardiac surgeon. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. SHIVAANI KUMMAR, Medical Oncology PORTLAND, OR - NPI 1053612341 shivaani kummar ohsu email Read More Contact Shivaani Kummar's Phone Number and Email Last Update 11/29/2022 2:55 AM Email s***@ohsu.edu Engage via Email Contact Number (***) ***-**** Engage via Phone Mobile Number (***) ***-**** Engage via Mobile HQ Phone Very few institutions do it well, but OHSU truly gets it, Kummar says. Cited by. A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, New England Journal of Medicine 378 (8), 731-739. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography The provider is located at 3181 Sw Sam Jackson Park Rd Portland, Or 97239 and the phone number is (503) 314-7168 Which is Dr. Shivaani Kummar specialty? & Kummar, S. Research output: Contribution to journal Comment/debate peer-review, Research output: Contribution to journal Review article peer-review, Research output: Contribution to journal Article peer-review, Powered by Pure, Scopus & Elsevier Fingerprint Engine 2023 Elsevier B.V, We use cookies to help provide and enhance our service and tailor content. 2001-2023 OHSU. However, high costs, long development t (Getty Images), Communications Manager, OHSU Knight Cancer Institute, Husband-wife team from Stanford University tapped to lead two cancer programs at OHSU, OHSU leading effort to make cancer trials more inclusive, Making Hepatitis C care easier when treatment seems impossible, Pill for skin disease also curbs excessive drinking, OHSU clinical trial tests exercise for multiple sclerosis treatment. Shivaani Kummar. Keep me signed in. We are asking this question from time to time, and we expect to uncover a globe-full of roads to Stanford. shivaani kummar ohsu email 2001-2022 Oregon Health & Science University. Early phase trials are conducted to test new treatments for cancer, while ensuring the highest standards of patient safety. And to train and inspire the next generation of doctors and scientists. Knight Cancer Institute | OHSU Knight Cancer Institute | OHSU Administrative Coordinator, Karri Garaventa My clinical work is focused on conducting early phase clinical trials, enrolling and caring for patients on these trials. (44 Ratings, Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, Clinical Cancer Research 18 (6), 1726-1734. Shivaani Kummar (OHSU) [email protected] Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. My patients. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Hamburger Menu x Home Shivaani Kummar. Most recently, he was the director for Stanford SRI Drug Discovery and Development Program, and he trained with Nobel laureate Herb Brown at Purdue University. Web Browser Accessibility, Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics, Shivaani Kummar, M.D., and her husband Sanjay Malhotra, Ph.D., will co-lead the Knight Cancer institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. 2001-2023 OHSU. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight. We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. The couple says their ultimate goal is to develop new effective therapies for cancer. (OHSU/Joe Rojas-Burke), Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for Health and Healing Building 2 on OHSU's South Waterfront campus, Aug. 23, 2021. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Dr. A Novel Artificial Intelligence-Powered Method for Prediction of Early Dr. Shivaani Kummar, Oncologist - FindaTopDoc Will you join us. Shivaani Kummar Director of Center for Experimental Therapeutics, Professor and Endowed Chair, Knight Cancer Institute The Knight Cancer Institute's Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. (h.c.), Ph.D., FAACR. They say they shared an interest in cancer drug discovery and development that grew after their marriage. These topic labels come from the works of this person. Drukers approach to team science is incorporated throughout the institutes infrastructure. S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Leadership The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. By using this website, we will assume that you agree to the terms and conditions of our privacy policy. In 2020, 470 Oregon residents from 28 counties consented to participate in clinical trial activities with the Knight Cancer Institute. Four questions with Shivaani Kummar, MD, FACP | OHSU Foundation Try restaurant style recipes at home. A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. OHSU is an equal opportunity affirmative action institution. The purpose of the study is to learn more about the study drug, VIP152, in combination with pembrolizumab in people with advanced or . 2022 ASCO Annual Meeting - Poster Session . Combining PARP Inhibitor with Immunotherapy - Does the Promise of Preclinical Data Translate to Clinic? She runs early phase clinical trials evaluating new treatments while ensuring highest standards of patient safety. Administrative Coordinator, Ingrid Studebaker She also leads the division of hematology & medical oncology in the OHSU School of Medicine. Dr. Shivaani Kummar is an oncologist practicing in Bethesda, MD. scripps institution of oceanography graduate programs; rosemont seneca advisors website In addition to her role as division head, Kummar will serve as co-director for a new center in the Knight Cancer Institute, theCenter for Experimental Therapeutics, which she will co-lead with Sanjay Malhotra, Ph.D. Kummar brings a wealth of experience in conducting clinical trials tailored to make early, informed decisions regarding the suitability of new drug candidates for further clinical investigation. I am humbled and inspired by the courage, grace and feeling of altruism that I find in each and every patient who chooses to participate in these trials. Trisha Silbernagel, RN, BSN, early-phase clinical trial unit manager, checks equipment on Aug. 23, 2021. Administrative Coordinator, Denise Hopkins February 17, 2023. Vol.49 No.07. Under his leadership, the Knight Cancer Institute is actively engaged in doing so., Brian Druker, M.D., Knight Cancer Institute director, JELD-WEN Chair of Leukemia Research; investigator, Howard Hughes Medical Institute. DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, S Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, Journal of clinical oncology 27 (16), 2705. Clinical Activity of the -Secretase Inhibitor PF-03084014 in Adults (h.c.), Ph.D., FAACR Director of CEDAR Sadik Esener, Ph.D. Director of precision oncology and SMMART Gordon Mills, M.D.,Ph.D. 2001-2022 Oregon Health & Science University. Tom Sellers was named lead research officer at OHSU Knight Cancer Institute. Together their goal is to find a cure for cancer. (OHSU/Joe Rojas-Burke), The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. Hung, M.D. BAL0891 . Share on print. Shivaani Kummar Dr. Kummar was recently appointed as Division Chief of Hematology and Oncology, and co-Director of the Center for Experimental Therapeutics, at the Oregon Health and Science University in Portland, Oregon. Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX Shivaani Kummar, M.D., FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. By continuing you agree to the use of cookies. Sort by citations Sort by year Sort by title. Office 3181 SW Sam Jackson Park Rd Portland, OR 97239 Phone+1 503-280-1223 Is this information wrong? The 13,000-square-foot early-phase research unit is located on the 12th floor of OHSUs Center for Health and Healing Building 2 on OHSUs South Waterfront campus. The two will co-lead the institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. Local: (503) 228-1730 | Toll Free: (800) 462-6608 The center is designed to advance innovation efforts within the Knight Cancer Institute to discover and develop new treatments for cancer, from early phase clinical trials, to drug development. Shivaani Kummar 1 2 , Apurva K Srivastava 3 , Tony Navas 3 4 , Fabiola Cecchi 5 6 , Young H Lee 5 7 , Donald P Bottaro 5 , Sook Ryun Park 1 8 , Khanh T Do 1 9 , Woondong Jeong 1 10 , Barry C Johnson 1 , Andrea R Voth 1 , Larry Rubinstein 11 , John J Wright 1 , Ralph E Parchment 3 , James H Doroshow 1 12 , Alice P Chen 13 Division of Hematology and Medical Oncology Faculty and Staff - OHSU Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. February 17, 2023. OHSU expands capacity for cancer clinical trials | OHSU News Email: [email protected] Call: 503-494-1080 Oregon Health & Science University. Yourinsurancecompany will also be able to inform you of any copayments, coinsurance, or deductibles that will be your responsibility. Dr. Kummar joined the OHSU Knight Cancer Institute from Stanford University in July 2020. Select a country/territory to view shared publications and projects. Title. Email: [email protected] Call: 503-494-1080 Oregon Health & Science University. OHSU is an equal opportunity affirmative action institution. Shivaani Kummar, M.D., FACP Lisa M. Coussens, M.D. This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. To find better ways to detect cancer. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D.